Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Literature DB >> 3032099

In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Abstract

The activity of LY146032, a new lipopeptide antibiotic, was compared in vitro with those of vancomycin, oxacillin, and ampicillin against 261 staphylococcal and 154 streptococcal isolates. The MICs of LY146032 and vancomycin were similar, but the bactericidal activity and killing kinetics of LY146032 were more pronounced.

Entities: Chemical

Mesh：

Substances：

Year: 1987 PMID： 3032099 PMCID： PMC174722 DOI： 10.1128/AAC.31.2.340

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

1 in total

1. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors: G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

1 in total

18 in total

1. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

Authors: K Vance-Bryan; T A Larson; J C Rotschafer; J P Toscano
Journal: Antimicrob Agents Chemother Date: 1992-10 Impact factor: 5.191

2. Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains.

Authors: A R Wanger; B E Murray
Journal: Antimicrob Agents Chemother Date: 1987-11 Impact factor: 5.191

3. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.

Authors: Q N Luu; T B Buxton; D R Nelson; J P Rissing
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-06 Impact factor: 3.267

4. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.

Authors: C W Stratton; C Liu; L S Weeks
Journal: Antimicrob Agents Chemother Date: 1987-08 Impact factor: 5.191

5. Bactericidal activity of vancomycin in cerebrospinal fluid.

Authors: M Nagl; C Neher; J Hager; B Pfausler; E Schmutzhard; F Allerberger
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

6. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001.

Authors: Ian A Critchley; Renée S Blosser-Middleton; Mark E Jones; Clyde Thornsberry; Daniel F Sahm; James A Karlowsky
Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191

7. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors: P Van der Auwera
Journal: Antimicrob Agents Chemother Date: 1989-10 Impact factor: 5.191

8. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.

Authors: J I Blenkharn; J H Darrell
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-08 Impact factor: 3.267

9. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.

Authors: C A Wood; H C Finkbeiner; S J Kohlhepp; P W Kohnen; D N Gilbert
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

10. Controlled release of vancomycin from cross-linked gelatine.

Authors: Domenico Tigani; Carola Zolezzi; Federico Trentani; Alessandro Ragaini; Michele Iafisco; Silvia Manara; Barbara Palazzo; Norberto Roveri
Journal: J Mater Sci Mater Med Date: 2007-10-04 Impact factor: 3.896